



GOVERNOR'S OFFICE OF
BUDGET AND PROGRAM PLANNING

Fiscal Note 2027 Biennium

Bill#/Title: HB0610.01: Revise preauthorization laws relating to healthcare

Primary Sponsor: Kerri Seekins-Crowe Status: As Introduced

☐ Included in the Executive Budget ☐ Needs to be included in HB 2 ☐ Significant Local Gov Impact
☐ Significant Long-Term Impacts ☒ Technical Concerns ☐ Dedicated Revenue Form Attached

FISCAL SUMMARY

	<u>FY 2026</u> <u>Difference</u>	<u>FY 2027</u> <u>Difference</u>	<u>FY 2028</u> <u>Difference</u>	<u>FY 2029</u> <u>Difference</u>
Expenditures				
Revenues				
Net Impact	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>
General Fund Balance				

Description of fiscal impact

HB 610 intends to streamline access to essential mental health medications for Medicaid recipients in Montana and directs the Department of Public Health and Human Services to eliminate prior authorization requirements for certain antipsychotic drugs, improving the efficiency of treatment for individuals with mental health conditions. By removing this administrative barrier, the bill seeks to ensure timely access to necessary medications and support better mental health outcomes.

FISCAL ANALYSIS

Assumptions

Department of Public Health and Human Services (department)


1. HB 610 intends to streamline access to essential mental health medications for Medicaid recipients in Montana and directs the department to eliminate prior authorization requirements for certain antipsychotic drugs, improving the efficiency of treatment for individuals with mental health conditions. By removing this administrative barrier, the bill seeks to ensure timely access to necessary medications and support better mental health outcomes.
2. The Diagnostic and Statistical Manual of Mental Disorders does not recognize or categorize drugs as effective. Thus, as written, HB 610 would not apply to any antipsychotic drugs and would have no fiscal impact to the department.

Fiscal Analysis Table

	<u>FY 2026</u> <u>Difference</u>	<u>FY 2027</u> <u>Difference</u>	<u>FY 2028</u> <u>Difference</u>	<u>FY 2029</u> <u>Difference</u>
<u>Fiscal Impact</u>				
<u>Expenditures</u>				
<u>Funding of Expenditures</u>				
<u>Revenues</u>				
<u>Net Impact to Fund Balance (Revenue minus Funding of Expenditures)</u>				
	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>

Technical Concerns

1. HB 610 provides that the department “may not require prior authorization under the Medicaid program for any antipsychotic drug approved by the federal drug administration that is recognized by the most recent edition of the Diagnostic and Statistical Manual of Mental Disorders adopted by the American Psychiatric Association as effective in the treatment of conditions that are specified in the manual.” There is no “federal drug administration.” There is the U.S. Drug Enforcement Administration, which enforces criminal and other laws concerning “scheduled <http://entdoaahs0881.gov/govinfo/fiscalnotes/obppamendmentteam/FiscalNotes.aspx> drugs” (controlled substances), and the U.S. Food and Drug Administration (FDA), which regulates food, drugs, biologics, cosmetics, and tobacco products.
2. As noted above, the Diagnostic and Statistical Manual of Mental Disorders does not recognize or categorize drugs as effective. Thus, as written, HB 610 would not apply to any antipsychotic drugs and would have no fiscal impact on the department.
3. The term “antipsychotic drug” is not defined in HB 610 and there does not appear to be a definition of the term in the Medicaid chapters of the Montana Code Annotated



Sponsor's Initials

2-25-2025

Date



Budget Director's Initials

2/25/2025

Date